Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan

S. Hisata (Tochigi, Japan), M. Bando (Tochigi, Japan), S. Homma (Tokyo, Japan), K. Kataoka (Aichi, Japan), T. Ogura (Kanagawa, Japan), S. Izumi (Tokyo, Japan), S. Sakamoto (Tokyo, Japan), Y. Saito (Tokyo, Japan), K. Watanabe (Kyoto, Japan), Y. Shimizu (Tochigi, Japan), M. Kato (Tokyo, Japan), N. Inase (Tokyo, Japan)

Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session: Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type: E-poster session
Number: 1847

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Hisata (Tochigi, Japan), M. Bando (Tochigi, Japan), S. Homma (Tokyo, Japan), K. Kataoka (Aichi, Japan), T. Ogura (Kanagawa, Japan), S. Izumi (Tokyo, Japan), S. Sakamoto (Tokyo, Japan), Y. Saito (Tokyo, Japan), K. Watanabe (Kyoto, Japan), Y. Shimizu (Tochigi, Japan), M. Kato (Tokyo, Japan), N. Inase (Tokyo, Japan). Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan. 1847

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: